---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-018211"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:47:55.356295+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Rhythm's Phase 3 EMANATE trial misses primary endpoints; post hoc signals in POMC/SRC1

## Summary
- Four substudies failed primary endpoint: placebo-adjusted BMI reductions of 4.3% (POMC/PCSK1), 3.6% (LEPR), 4.0% (SRC1), 1.7% (SH2B1); all p>0.05.
- Post hoc LOCF analysis showed significant BMI reductions: POMC/PCSK1 -5.5% (p=0.0010), SRC1 -6.2% (p<0.0001) vs placebo.
- Completer analysis: placebo-adjusted BMI -9.7% (POMC/PCSK1, n=41, p=0.0002) and -8.0% (SRC1, n=29, p=0.0158).
- Safety profile consistent with prior studies; no new signals. Common AEs: skin hyperpigmentation, injection-site reactions.
- Rhythm to evaluate next-gen MC4R agonists bivamelagon and RM-718 for SRC1 and POMC; continuing DAYBREAK exploratory work.

## SEC filing metadata
- accession: 0001628280-26-018211
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000162828026018211/0001628280-26-018211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000162828026018211/rytm-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-018211
- JSON: https://secwatch.observer/filing/0001628280-26-018211.json
- Plain text: https://secwatch.observer/filing/0001628280-26-018211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.